GB8519310D0
(en)
*
|
1985-07-31 |
1985-09-04 |
Zyma Sa |
Granular active substances
|
US4892742A
(en)
*
|
1985-11-18 |
1990-01-09 |
Hoffmann-La Roche Inc. |
Controlled release compositions with zero order release
|
IE63321B1
(en)
*
|
1986-02-03 |
1995-04-05 |
Elan Corp Plc |
Drug delivery system
|
US5342622A
(en)
*
|
1986-05-16 |
1994-08-30 |
The State Of Victoria |
Subdermal biocompatible implants
|
US4789549A
(en)
*
|
1987-03-09 |
1988-12-06 |
Warner-Lambert Company |
Sustained release dosage forms
|
DE3720757A1
(de)
*
|
1987-06-24 |
1989-01-05 |
Bayer Ag |
Dhp-manteltablette
|
FR2618073B1
(fr)
*
|
1987-07-16 |
1990-09-07 |
Pf Medicament |
Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
|
US4792452A
(en)
*
|
1987-07-28 |
1988-12-20 |
E. R. Squibb & Sons, Inc. |
Controlled release formulation
|
US5230901A
(en)
*
|
1988-03-23 |
1993-07-27 |
Knoll Ag |
Sustained release tablet of a mixture of alginates and polyacrylates
|
DE3809764A1
(de)
*
|
1988-03-23 |
1989-10-05 |
Knoll Ag |
Mischung aus alginaten und polyacrylaten und deren verwendung
|
US5019397A
(en)
*
|
1988-04-21 |
1991-05-28 |
Alza Corporation |
Aqueous emulsion for pharmaceutical dosage form
|
IE60383B1
(en)
*
|
1988-05-27 |
1994-07-13 |
Elan Corp Plc |
Controlled release pharmaceutical formulation
|
NO882653D0
(no)
*
|
1988-06-15 |
1988-06-15 |
Apothekernes Lab |
Doseringsform.
|
US5612059A
(en)
*
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
AU622254B2
(en)
*
|
1989-01-03 |
1992-04-02 |
Sterling Drug Inc. |
Controlled-release, low dose aspirin
|
US4970081A
(en)
*
|
1989-01-03 |
1990-11-13 |
Sterling Drug Inc. |
Controlled-release, low-dose aspirin formulation and method of treating vascular occlusive disease therewith
|
US5108756A
(en)
*
|
1989-01-12 |
1992-04-28 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
IL92966A
(en)
*
|
1989-01-12 |
1995-07-31 |
Pfizer |
Hydrogel-operated release devices
|
US5030452A
(en)
*
|
1989-01-12 |
1991-07-09 |
Pfizer Inc. |
Dispensing devices powered by lyotropic liquid crystals
|
DD295760A5
(de)
*
|
1989-01-31 |
1991-11-14 |
Martin-Luther-Universitaet Halle Wittenberg,De |
Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
|
US4992277A
(en)
*
|
1989-08-25 |
1991-02-12 |
Schering Corporation |
Immediate release diltiazem formulation
|
US5000962A
(en)
*
|
1989-08-25 |
1991-03-19 |
Schering Corporation |
Long acting diltiazem formulation
|
US6482516B1
(en)
*
|
1993-07-20 |
2002-11-19 |
Banner Pharmacaps, Inc. |
Enrobed tablet
|
EP0418596A3
(en)
*
|
1989-09-21 |
1991-10-23 |
American Cyanamid Company |
Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
|
IL95423A
(en)
*
|
1989-09-21 |
1994-11-11 |
American Cyanamid Co |
Pulse system for delivery of minocycline once daily
|
US5175003A
(en)
*
|
1990-04-06 |
1992-12-29 |
Biosytes Usa, Inc. |
Dual mechanism controlled release system for drug dosage forms
|
US5013728A
(en)
*
|
1990-05-04 |
1991-05-07 |
Colgate - Palmolive Company |
Composition for treating osteoporosis and hormonal imbalance
|
JP2572673B2
(ja)
*
|
1990-07-25 |
1997-01-16 |
エスエス製薬株式会社 |
徐放性錠剤
|
EP0542926B1
(en)
*
|
1990-08-07 |
1995-02-15 |
Pfizer Inc. |
Use of interfacially-polymerized membranes in delivery devices
|
US5153005A
(en)
*
|
1990-12-11 |
1992-10-06 |
Colgate-Palmolive Company |
Composition and method for preventing fluorosis
|
US5288505A
(en)
*
|
1991-06-26 |
1994-02-22 |
Galephar P.R., Inc., Ltd. |
Extended release form of diltiazem
|
DE4138513A1
(de)
*
|
1991-11-23 |
1993-05-27 |
Basf Ag |
Feste pharmazeutische retardform
|
US5407686A
(en)
*
|
1991-11-27 |
1995-04-18 |
Sidmak Laboratories, Inc. |
Sustained release composition for oral administration of active ingredient
|
US5472712A
(en)
*
|
1991-12-24 |
1995-12-05 |
Euroceltique, S.A. |
Controlled-release formulations coated with aqueous dispersions of ethylcellulose
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US5580578A
(en)
*
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5681585A
(en)
*
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US7070806B2
(en)
*
|
1992-01-27 |
2006-07-04 |
Purdue Pharma Lp |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5262173A
(en)
*
|
1992-03-02 |
1993-11-16 |
American Cyanamid Company |
Pulsatile once-a-day delivery systems for minocycline
|
US6129930A
(en)
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
US6676967B1
(en)
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
HU213407B
(en)
*
|
1993-12-09 |
1997-06-30 |
Egyt Gyogyszervegyeszeti Gyar |
Process for producing tablet with diffusive-osmotic release
|
US5945125A
(en)
*
|
1995-02-28 |
1999-08-31 |
Temple University |
Controlled release tablet
|
AU2068797A
(en)
*
|
1996-01-29 |
1997-08-20 |
Edward Mendell Co. Inc. |
Sustained release excipient
|
SE9603667D0
(sv)
*
|
1996-10-08 |
1996-10-08 |
Astra Ab |
Pharmaceutical compositions
|
US5800832A
(en)
*
|
1996-10-18 |
1998-09-01 |
Virotex Corporation |
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
|
CA2270975C
(en)
|
1997-07-02 |
2003-04-01 |
Euro-Celtique, S.A. |
Stabilized sustained release tramadol formulations
|
US20050048102A1
(en)
*
|
1997-10-16 |
2005-03-03 |
Virotex Corporation |
Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
US6432448B1
(en)
*
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
US6500462B1
(en)
*
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US7108866B1
(en)
|
1999-12-10 |
2006-09-19 |
Biovall Laboratories International Srl |
Chronotherapeutic diltiazem formulations and the administration thereof
|
EP1239839A2
(en)
|
1999-12-23 |
2002-09-18 |
Pfizer Products Inc. |
Hydrogel-driven layered drug dosage form comprising sertraline
|
WO2002043694A2
(en)
|
2000-11-28 |
2002-06-06 |
Fmc Corporation |
Edible pga(propylene glycol alginate) coating composition
|
US6932861B2
(en)
|
2000-11-28 |
2005-08-23 |
Fmc Corporation |
Edible PGA coating composition
|
EP1408976B3
(en)
*
|
2001-07-20 |
2010-08-25 |
Psychogenics Inc. |
Treatment for attention-deficit hyperactivity disorder
|
US6663896B1
(en)
|
2001-08-01 |
2003-12-16 |
Alvin S. Blum |
Delayed release aspirin for vascular obstruction prophylaxis
|
US6602911B2
(en)
*
|
2001-11-05 |
2003-08-05 |
Cypress Bioscience, Inc. |
Methods of treating fibromyalgia
|
AR039162A1
(es)
*
|
2002-03-28 |
2005-02-09 |
Synthon Bv |
Formulaciones de venlafaxina de liberacion extendida
|
SE0201110D0
(sv)
*
|
2002-04-12 |
2002-04-12 |
Astrazeneca Ab |
New film coating
|
SE0202353D0
(sv)
*
|
2002-08-01 |
2002-08-01 |
Astrazeneca Ab |
New film coating
|
US20050084531A1
(en)
*
|
2003-10-16 |
2005-04-21 |
Jatin Desai |
Tablet with aqueous-based sustained release coating
|
GB0400452D0
(en)
*
|
2004-01-09 |
2004-02-11 |
Norton Healthcare Ltd |
A pharmaceutical composition
|
US20060099262A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Biokey, Inc. |
Methods and formulations for making controlled release oral dosage form
|
US7994220B2
(en)
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
AU2007275581B2
(en)
|
2006-07-21 |
2011-09-08 |
Biodelivery Sciences International, Inc. |
Transmucosal delivery devices with enhanced uptake
|
AU2008286914B2
(en)
*
|
2007-08-13 |
2014-10-02 |
Ohemo Life Sciences Inc. |
Abuse resistant drugs, method of use and method of making
|
US20120244218A1
(en)
|
2011-03-25 |
2012-09-27 |
Durkee Shane E |
Calcium supplement
|
BR112014003651B1
(pt)
|
2011-08-18 |
2022-03-29 |
Biodelivery Sciences International, Inc |
Dispositivos mucoadesivos resistentes ao mau uso para a liberação de buprenorfina
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
EP2976082A4
(en)
|
2013-03-15 |
2016-05-11 |
Inspirion Delivery Technologies Llc |
MISS-INFANT COMPOSITIONS AND METHODS OF USE
|
US10729685B2
(en)
|
2014-09-15 |
2020-08-04 |
Ohemo Life Sciences Inc. |
Orally administrable compositions and methods of deterring abuse by intranasal administration
|
US10434113B2
(en)
|
2016-12-16 |
2019-10-08 |
The Charlotte Mecklenburg Hospital Authority |
Compositions and methods for treating muscular dystrophy and other disorders
|
US20200061092A1
(en)
*
|
2018-08-24 |
2020-02-27 |
The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health |
Methods and compositions for treating disorders associated with muscle weakness
|